[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100613746":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":23,"centralContacts":36,"locations":42,"responsibleParty":66,"collaborators":68,"id":71,"slug":72,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":79,"sex":80,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":23,"studyType":86,"phases":87,"briefSummary":89,"conditions":90,"keywords":93,"overallStatus":45,"whyStopped":23,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},{"fullName":5,"class":6},"ContextVision AB","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort","EXPERIMENTAL","Adult healthy volunteers as well as subjects who have a diagnosis, or suspected, of having MASLD or are deemed to meet the high-risk cardiometabolic criteria.",[13,14,15,16],"Device: Verasonics NXT Data Acquisition System","Device: Philips EPIQ Elite","Device: EchoSense FibroScan","Device: Philips 3T Ingenia Elition",[18,24,28,32],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"DEVICE","Verasonics NXT Data Acquisition System","A research ultrasound imaging device to capture raw radiofrequency ultrasound data for the following parameters:\n\n* B-mode imaging\n* Attenuation coefficient\n* Backscatter coefficient\n* Speed of sound\n* Shear wave elastography",[9],null,{"type":19,"name":25,"description":26,"armGroupLabels":27,"otherNames":23},"Philips EPIQ Elite","A premium ultrasound system with software package to support imaging research studies.",[9],{"type":19,"name":29,"description":30,"armGroupLabels":31,"otherNames":23},"EchoSense FibroScan","A non-invasive ultrasound solution that accurately measures liver stiffness and liver steatosis.",[9],{"type":19,"name":33,"description":34,"armGroupLabels":35,"otherNames":23},"Philips 3T Ingenia Elition","A 3-tesla magnetic resonance imaging (MRI) system",[9],[37],{"name":38,"role":39,"phone":40,"phoneExt":23,"email":41},"Laura Sissons-Ross Research Manager","CONTACT","206-616-0397","lsissons@uw.edu",[43],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"University of Washington","RECRUITING","Seattle","Washington","98195","United States","US",{"type":52,"coordinates":53},"Point",[54,55],-122.33207,47.60621,{"lat":55,"lon":54},[58,61,64],{"name":59,"role":39,"phone":40,"phoneExt":23,"email":60},"Research Fellow","madhvi@uw.edu",{"name":62,"role":63,"phone":23,"phoneExt":23,"email":23},"Rotonya Carr, MD","PRINCIPAL_INVESTIGATOR",{"name":65,"role":63,"phone":23,"phoneExt":23,"email":23},"Manish Dhyani, MD",{"type":67,"investigatorFullName":23,"investigatorTitle":23,"investigatorAffiliation":23,"oldNameTitle":23,"oldOrganization":23},"SPONSOR",[69],{"name":44,"class":70},"OTHER","100613746","development-of-a-quantifiable-ultrasound-biomarker-for-hepatic-steatosis-100613746",false,"NCT07270601","Development of a Quantifiable Ultrasound Biomarker for Hepatic Steatosis","Development and Diagnostic Evaluation of a Novel Quantifiable Ultrasound Based Multi-parametric Biomarker for Hepatic Steatosis in Patients With Suspected MASLD ( LYNX )","LYNX","Inclusion Criteria:\n\nDiseased subject:\n\n* Adult patients (age 18 - 75 years)\n* Consent to participate in the study\n* Diagnosed or suspected MASLD from the hepatology clinic, OR\n* High-risk population meeting the adult cardiometabolic criteria (defined as the presence of at least one of the following: diabetes, obesity (BMI ≥ 25 kg\u002Fm2), hypercholesterolemia, and hypertension)\n\nHealthy volunteer:\n\n* Adult patients (age 18 - 75 years)\n* Consent to participate in the study\n* No suspicion of MASLD by laboratory\u002Fimaging\u002Fclinical examinations\n* Absence of known pre-existing conditions (metabolic syndrome, diabetes mellitus, obesity, insulin resistance, dyslipidemia, etc.)\n\nExclusion Criteria:\n\n* Pregnancy or nursing.\n* Contraindications to MRI including, but not limited to, severe claustrophobia, pacemaker, or existing metallic\u002Fmechanical implant(s).\n* Acute illness\u002Fcognitive impairment resulting in an inability to cooperate with the MRI and ultrasound breath-holding instructions.\n* BMI \\> 35 kg\u002Fm2\n* History of excessive alcohol consumption according to the updated MASLD criteria (\\>2 drinks\u002Fday OR \\>210 grams\u002Fweek for males AND \\>1 drink\u002Fday OR \\>140 grams\u002Fweek for females) or drug use over the past 2 years.\n* Known acute or chronic hepatitis; or other etiology of liver disease.\n* Presence of known congenital hepatic anomaly.\n* Known cirrhosis\n* Known active cancer",true,"ALL","18 Years","75 Years",{"count":84,"type":85},110,"ESTIMATED","INTERVENTIONAL",[88],"NA","The research study is considering a non-invasive way to measure the percentage of fat in the liver using ultrasound. This could help detect early signs of a very common condition called metabolic dysfunction-associated steatotic liver disease (MASLD). Current tests, like MRI or biopsy, can be expensive or invasive. If successful, this ultrasound tool could become an easier and more accessible way to monitor liver health - especially for people with obesity, diabetes, high blood pressure, or high cholesterol.",[91,92],"MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease","NAFLD - Non-Alcoholic Fatty Liver Disease",[94,95,96,97,98,99],"MASLD","NAFLD","Ultrasound","Steatosis","Fibrosis","MRI-PDFF","2025-11-26",{"date":102,"type":103},"2025-12-08","ACTUAL",{"date":105,"type":103},"2025-11-17",{"date":107,"type":85},"2026-12-31",{"name":5,"class":6},1]